Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II study to Evaluate JadiCell for the Treatment of Brain Injuries

Next Previous
Trial Profile

A phase I/II study to Evaluate JadiCell for the Treatment of Brain Injuries

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 24 Dec 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 17 Dec 2020 According to a Therapeutic Solutions International media release, the company announced the filing of an Investigational New Drug (IND) application seeking permission from the Food and Drug Administration (FDA) to initiate this study.
  • 05 Oct 2020 New trial record
  • 28 Sep 2020 According to a Therapeutic Solutions International media release, the company is working to assemble the Investigational New Drug (IND) Application with the FDA to begin clinical trials on this terrible condition (brain injuries, including chronic traumatic encephalopathy).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top